A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
50actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-20 | actual | When the study began enrolling |
| Primary completion | 2025-04-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-11 | actual | The whole study's end, after follow-up |
| First posted | 2024-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Obesity
Interventions
- Drug: Placebo
- Drug: Rosuvastatin
- Drug: Midazolam
- Drug: Omeprazole
- Drug: PF-06954522
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Reporting Adverse Events
measured Baseline through Week 14
Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities
measured Baseline through Week 14
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
measured Baseline through Week 14
Number of Participants With Clinically Significant Change From Baseline in 12-Lead ECGs
measured Baseline through Week 14
Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
measured Baseline through Week 14
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed